Indivior (INDV) to Release Earnings on Thursday

Indivior (NASDAQ:INDV) will likely be releasing its earnings data before the market opens on Thursday, April 24th. Analysts expect Indivior to post earnings of $0.22 per share and revenue of $240.13 million for the quarter. Indivior has set its FY 2025 guidance at EPS.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.32 EPS for the quarter, meeting the consensus estimate of $0.32. The company had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, analysts expect Indivior to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Indivior Stock Performance

INDV opened at $9.06 on Thursday. Indivior has a 1 year low of $7.33 and a 1 year high of $19.51. The company’s 50 day simple moving average is $9.53 and its 200 day simple moving average is $10.33. The stock has a market capitalization of $1.25 billion, a PE ratio of -25.89 and a beta of 0.93.

Analyst Ratings Changes

INDV has been the subject of a number of research analyst reports. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Piper Sandler dropped their target price on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.